Needham Rates Neurocrine Biosciences (NBIX) Buy

On October 16, 2026, Needham reiterated its Buy rating on Neurocrine Biosciences, Inc. (NBIX) with a price target of $204.00. This target remains unchanged from its previous level. At the time of the announcement, Neurocrine shares traded at $135.90, a decrease from the prior close of $146.23.

Needham's Call on Neurocrine Biosciences

Needham's latest assessment reflects confidence in Neurocrine's business prospects. The $204 target suggests analysts expect significant upside from the current trading price. With a solid foundation in developing treatments for neurological disorders, investors may find this rating supportive.

Other Institutional Activity in Neurocrine Biosciences

Several notable funds have adjusted their stakes in Neurocrine. Blackrock Inc. grew its holdings by 326,594 shares, bringing its total to about 13.7 million shares valued at approximately $1.86 billion. JPMorgan Chase & Co. increased its position by 956,699 shares, now holding 6.4 million shares worth about $869.5 million. Dodge & Cox Inc. added 123,425 shares for a total of 5.6 million shares valued at around $758.9 million. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC also increased their positions, adding 247,664 and 33,388 shares, respectively.

Neurocrine Biosciences, Inc. Stock Down 0.8%

Neurocrine shares have been trading lower, with the current price of $135.90 significantly below the 52-week high of $186.12. The stock is currently around 15% above its 52-week low of $122.14. This performance may catch the attention of investors, especially given the bullish target from Needham.

Recent Earnings

In its most recent fiscal year, Neurocrine reported revenues of approximately $3.37 billion, reflecting a growth rate of about 39.5%. The company's earnings per share (EPS) stood at $6.84, and it maintained a net margin of 20.9%. The next earnings report is scheduled for October 28, 2026, which could provide further insights into its financial health.

Insider Buying and Selling at Neurocrine Biosciences, Inc.

Insider activity at Neurocrine includes multiple transactions by Darin Lippoldt, the Chief Legal Officer. Lippoldt purchased 9,800 shares at a price of $81.49 on June 29, 2026, totaling about $798,602. Prior to that, he bought 200 shares on June 26, 2026, for about $16,298. There were also planned sales of shares at a higher price, indicating a mix of trading strategies.

Analysts Set New Price Targets

Analysts have varying views on Neurocrine's future. On October 12, 2026, BMO Capital maintained a Market Perform rating with a target of $150. Meanwhile, UBS kept its Buy rating and set a target of $214, down from $231, on September 29, 2026. Overall, the consensus suggests a strong Buy with an average price target of $208.40 based on 29 opinions.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. focuses on developing pharmaceuticals for neurological and psychiatric disorders. With its headquarters in San Diego, California, the company has around 2,500 employees. This reiteration of a Buy rating from Needham comes as the company continues to expand its innovative product pipeline.

Bottom Line

Investors should watch for Neurocrine's next earnings report on October 28, 2026, for updates on performance and direction. The recent analyst coverage reflects confidence in the company's potential, even as shares trade below their target price. Remember that Needham's ratings are backward-looking and based on prior positions.